Introduction {#sec1}
============

Osteoarthritis (OA) is identified as the most common musculoskeletal disorder with deregulation in the inflammatory pathway and apoptosis. The degenerative joint disease is associated with loss of cartilage function which mainly occurs as an imbalance between anabolic and catabolic pathways of matrix formation, with more pronounced catabolism of cartilage \[[@cit0001]\]. The associated risk factors of osteoarthritis include age, genetic predisposition, injury, obesity, etc. An important contributor to cartilage function is chondrocytes, cells which are involved in production and formation of matrix proteins. Terminally differentiated chondrocytes undergo apoptosis with ultimate matrix calcification and vascular invasion of cartilage. Thus, the principle functional loss of chondrocytes is the major event in osteoarthritis. Oxidative stress and activation of inflammation has been known to be an important mediator in the development of osteoarthritis \[[@cit0002], [@cit0003]\]. Thus, an effective protective strategy could be established by targeting oxidative stress and apoptosis, thereby improving the functional status of chondrocytes. Recently, there has been much focus on natural compounds with potent antioxidant properties, by which they target redox signaling and ameliorate negative effects leading to disease status \[[@cit0004], [@cit0005]\]. In the present study, we aimed to study the potential role of lutein against monosodium iodoacetate (MIA) induced osteoarthritis. Lutein (C~40~H~56~O~2~) is a tetraterpenoid that has been identified as a potent antioxidant. Rich sources are dark green leafy vegetables, eggs and fruits. The hydroxyl group of lutein scavenges reactive oxygen species and exerts protection against oxidative stress and inflammatory diseases \[[@cit0006]--[@cit0008]\]. Lutein suppresses arthrosclerosis by reducing oxidative stress and inflammation \[[@cit0009]\]. Anti-inflammatory effects of lutein in lipopolysaccharide (LPS)-induced inflammation in macrophages and skin inflammation were mediated through downregulating inflammatory proteins and cytokine expression \[[@cit0009], [@cit0010]\]. Furthermore, the protective role of lutein against ischemic injury in the small intestine and kidney \[[@cit0011], [@cit0012]\] has been reported. Lutein's protection against paracetamol, carbon tetrachloride and ethanol induced liver damage is mediated through its antioxidant effects \[[@cit0013]\]. In this study, we aimed to analyze the action of lutein against osteoarthritis by evaluating oxidative stress and inflammatory mechanisms.

Material and methods {#sec2}
====================

Chemicals {#sec2.1}
---------

Lutein, minimum essential Eagle's medium, fetal bovine serum (FBS), trypsin, penicillin, streptomycin, DCF-DA (dichloro-dihydro-fluorescein diacetate), and DiOC~6~ (3,3'- dihexyloxacarbocyanine iodide) were purchased from Sigma Aldrich Chemicals Private Limited, USA. Primary monoclonal antibodies (NF-κB, Nrf2, HO-1, COX-2, NQO1) and secondary antibodies were purchased from Cell Signaling Technology, USA. ELISA kits (IL-6, IL-1β, TNF-α and caspase-3) were procured from Abcam, USA.

Cell culture and treatment schedule {#sec2.2}
-----------------------------------

Primary rat chondrocytes were used for the present study. The isolation and cell culture were carried out as described previously \[[@cit0014]\]. All the protocols were approved by the animal ethics committee at the Department of Orthopedics, Xinxiang Central Hospital, Xinxiang, China. Five-week-old Sprague-Dawley rats were used for the present study. The articular cartilage from the femoral heads of rats were excised and digested in trypsin-EDTA for 20 min followed by collagenase II treatment for 3 h. The primary chondrocytes were cultured in minimum essential Eagle's medium supplemented with 10% FBS and antibiotics. The chondrocytes at 3--5 passages were used for all the experiments. The cytotoxic concentration of MIA was determined and the protective dose of lutein was identified by pre-treating the cells with different concentrations of lutein followed by MIA. The shortlisted concentrations of MIA and lutein were used for further studies.

Briefly, articular cartilages of femoral heads were harvested from the 4-week-old male Sprague-Dawley rats. The cartilage pieces were digested with trypsin--EDTA and 0.2% Collagenase II (Sigma, St. Louis, MO) for 15 min and 3 h, respectively. The chondrocytes were cultured in Mini-mum essential Eagle's medium (MEM, Gibco, New York, NY) at 378°C in 5% CO~2~. For all experiments, the cells of early passages (primary to 3) were used.

Cell viability {#sec2.3}
--------------

Cell viability was assessed by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay. Briefly, cells (1 × 10^5^) were seeded and treated with different concentrations of MIA (2, 4, 6, 8 10 μM) for 24 and 48 h. The IC~50~ value was determined. Further, cytoprotective concentration was determined by treating with lutein (0.5, 1, 5 and 10 μM) for 24 h followed by MIA treatment. After the complete treatment schedule, cells were incubated with MTT (5 mg/ml) and resulting formazan crystals were dissolved in DMSO (dimethyl sulfoxide) and the absorbance was read at 570 nm. Cell viability was calculated by comparing the values to that of control cells \[[@cit0015]\].

Intracellular reactive oxygen species (ROS) generation {#sec2.4}
------------------------------------------------------

For ROS determination, the cells (1 × 10^5^) were treated with lutein for 24 h, followed by DCF-DA for 30 min. After that the cells were washed in PBS and treated with MIA for 48 h. The cells were trypsinized and suspended in PBS and ROS levels were measured fluorimetrically (excitation wavelength 480 nm, emission wavelength 520 nm). The results were expressed as % DCF fluorescence per mg of protein samples compared to the control group \[[@cit0016]\].

Lipid peroxidation {#sec2.5}
------------------

After treatment, cells were incubated in 8% sodium dodecyl sulfate (SDS); 0.8% thiobarbituric acid (TBA) in 20% acetic acid and heated for 1 h at 90°C. A butanol/pyridine mixture was added and it was shaken vigorously, then centrifuged at 4000 rpm for 10 min, and the organic layer was read at 532 nm. The lipid peroxide content was expressed as *n* moles of TBA reactants/mg of protein \[[@cit0017]\].

Antioxidant enzyme activities {#sec2.6}
-----------------------------

Superoxide dismutase (SOD) activity: The SOD activity was determined as described by Sun *et al.* \[[@cit0018]\]. The assay is based on reduction of nitro blue tetrazolium (NBT). 1 U of SOD activity = amount required for 50% inhibition of nitro blue tetrazolium chloride (NBT) reduction. The SOD activity is expressed as U/mg of protein. Catalase (CAT) activity: The activity was determined according to the method described by Aebi (1974) \[[@cit0019]\]. The reaction mixture contained tissue homogenate and 30 mM H~2~O~2~ in a 50 mM phosphate buffer (pH 7.0). The activity was estimated by the decrease in absorbance of H~2~O~2~ at 240 nm. Glutathione-S-transferase (GST) activity: The reaction between 1-chloro-2,4-dinitrobenzene (CDNB) and reduced glutathione results in formation of dinitrophenylthioether, which is measured at 340 nm \[[@cit0020]\]. 1 U = amount of enzyme producing 1 mmol of CDNB-GSH conjugate/min. Glutathione peroxidase (GPx) activity: The GPx activity was determined as described by Paglia and Valentine (1967) \[[@cit0021]\]. The oxidized glutathione (GSSG) is reduced by glutathione reductase and NADPH (nicotinamide adenine dinucleotide phosphate). The oxidation of NADPH to NADP^+^ is measured by the decrease in absorbance at 340 nm. GPx activity is expressed as U/mg of protein.

Mitochondrial membrane potential (Δψm) {#sec2.7}
--------------------------------------

The cells (1 × 10^5^) were treated with lutein for 24 h followed by MIA. After treatment, the cells were washed with PBS and treated with DiOC~6~ (3) and incubated for 1 h. The fluorescence intensity was measured (excitation wavelength of 488 nm and emission wavelength at 500 nm). The mitochondrial membrane potential was calculated per mg of protein, while the control was set to 100%.

ELISA: IL-6, TNF-α, IL-1β and caspase-3 levels {#sec2.8}
----------------------------------------------

After the treatment schedule mentioned above, the supernatant was analyzed for interleukins levels of TNF-α, IL-1β and IL-6 levels using ELISA kits (Sigma). The levels of interleukins were expressed as pg/ml. The cellular protein was analyzed for caspase-3 activity. Results were expressed as RU/mg of protein. The absorbance was measured using an ELISA reader (MTP-800 Microplate reader; Corona Electric, Tokyo, Japan).

Western blot {#sec2.9}
------------

After treatment, the cells were treated with RIPA lysis buffer for isolation of whole cell protein extract. The nuclear extract was isolated for determining the expression of NF-κB and Nrf2. The samples (50 μg protein) were separated on 10% SDS-PAGE gels and transferred onto polyvinylidene fluoride (PVDF) membranes. After protein transfer, non-specific sites were blocked with 5% nonfat dried milk for 1 h at room temperature. The membrane was washed with TBST and incubated with primary mouse monoclonal antibodies against NF-κB, COX-2, Nrf2, HO-1 and NQO1 (1 : 1000) at 4°C overnight. Followed by TBST wash, the membrane was incubated for 1 h with secondary peroxidase-conjugated goat anti-mouse or -rabbit IgG (1 : 5000--1 : 10,000). The bands were visualized with an enhanced chemiluminescence (ECL) system according to the manufacturer's instructions. Densitometric analyses of the western blot bands were performed using Image J software (GE Healthcare Life Sciences).

Statistical analysis {#sec2.10}
--------------------

The data were analyzed using one-way analysis of variance (ANOVA) followed by Tukey's multiple comparison test. All the experiments were performed thrice in triplicate to ensure reproducibility.

Results {#sec3}
=======

Protective effect of lutein against MIA-induced cytotoxicity {#sec3.1}
------------------------------------------------------------

In order to identify the cytotoxic concentration of MIA, the MTT assay was performed. Monosodium iodoacetate caused dose-dependent cell death compared to control cells. The results show that MIA at a concentration of 4 μM for 48 h showed the IC~50~ value. Further, the cytoprotective effect of lutein was tested at this dose. Lutein was pre-treated for 24 h at different concentrations followed by MIA treatment. Cells treated with 1 μM of lutein showed significant cytoprotection and increased the cell viability to 95%. Cells treated with lutein alone did not show any cytotoxic effect at any of the tested dosages ([Figures 1 A](#f0001){ref-type="fig"}, [B](#f0001){ref-type="fig"}). Human plasma levels of lutein have been demonstrated to be in the range of 0.25--0.85 μM \[[@cit0022]\]; thus the concentration of 1 μM lutein was used for further studies.

![Effect of MIA and lutein against primary chondrocyte cells. Cells were treated with MIA for 24 and 48 h. IC50 concentration was used to determine the protective effect of lutein against MIA-induced cell death. Cell viability was measured using MTT assay. Results were expressed as % cell viability compared to control. Results are given as the mean ± SEM. **A** -- \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001, when compared to control group. **B** -- \*\**p* \< 0.01, \*\*\**p* \< 0.001 when compared to MIA treatment (One-way ANOVA followed by Tukey's multiple comparison). NS -- non-significant compared to control group](AMS-14-27549-g001){#f0001}

Lutein protected against MIA-induced oxidative stress {#sec3.2}
-----------------------------------------------------

The results showed that MIA treatment resulted in a significant increase in oxidative stress status which was reflected in increased ROS and lipid peroxide content compared to control cells. Lutein pre-treatment followed by MIA treatment significantly reduced the ROS and lipid peroxide content compared to MIA-treated cells ([Figures 2 A](#f0002){ref-type="fig"}, [B](#f0002){ref-type="fig"}).

![Lutein reduces MIA-induced oxidative stress. **A** -- The results are expressed as nanomoles of TBARS formed/mg of protein. **B** -- The results are expressed as % DCF fluorescence when compared to control. Results are given as the mean ± SEM. \*\*\**p* \< 0.001, when compared to control group. +++*p* \< 0.001, when compared to MIA treatment. NS -- non-significant compared to control group (One-way ANOVA followed by Tukey's multiple comparison)](AMS-14-27549-g002){#f0002}

Lutein protected MIA-induced toxicity through Nrf2 upregulation {#sec3.3}
---------------------------------------------------------------

Nrf2 is a transcription factor involved in regulating redox homeostasis by upregulating antioxidant status. In the present study, we found that MIA treatment showed significant downregulation of Nrf2 and its downstream target antioxidant genes HO-1 and NQO-1. Furthermore, various antioxidant enzymes involved in balancing redox homeostasis such as SOD, CAT, GST and GPx were significantly downregulated compared to the control cells. Treatment with lutein showed cytoprotection by significant upregulation of Nrf2, NQO-1 and HO-I. Moreover, there was a concomitant increase in the antioxidant status compared to MIA-treated cells ([Figures 3](#f0003){ref-type="fig"}, [4](#f0004){ref-type="fig"}).

![Lutein improves antioxidant mechanism: upregulation of Nrf2, HO-1 and NQO1 expression. Protein expression was analyzed through western blot analysis. Results were expressed as mean ± SEM. Densitometric analysis show significant downregulation of Nrf2, HO-1 and NQO1 expression in MIA treatment. Lutein treatment upregulated the protein expression compared to MIA treatment. \*\*\**p* \< 0.001, when compared to control group. +++*p* \< 0.001, when compared to MIA treatment. NS -- non-significant compared to control group](AMS-14-27549-g003){#f0003}

![Lutein enhances antioxidant enzyme activities. Results are given as the mean ± SEM. SOD, CAT, GST and GPx expressed in units/mg protein. \*\*\**p* \< 0.001 when compared to control group. +++*p* \< 0.001 when compared to MIA treatment. NS--non-significant compared to control group (One-way ANOVA followed by Tukey's multiple comparison)](AMS-14-27549-g004){#f0004}

Lutein protected against MIA-induced inflammation {#sec3.4}
-------------------------------------------------

Oxidative stress induces activation of inflammatory responses through NF-κB. In the present study, MIA showed significant upregulation of NF-κB and the downstream inflammatory gene COX-2 compared to the control. However, lutein pre-treatment significantly downregulated the protein levels of NF-κB and COX-2 compared to MIA-treated cells and exerted an anti-inflammatory effect ([Figure 5 A](#f0005){ref-type="fig"}). In order to determine role of lutein and MIA on inflammatory cytokines, the levels of IL-6, IL-1β and TNF-α were determined. Cells treated with MIA showed significant upregulation of inflammatory cytokines compared to the control cells. However, treatment with lutein reduced the levels of cytokines compared to those of MIA-treated cells ([Figure 5 B](#f0005){ref-type="fig"}).

![Lutein shows anti-inflammatory effect: downregulation of NF-κB and COX-2 and inflammatory cytokines. **A** -- Protein expression of NF-κB and COX-2 was analyzed through western blot analysis. Results were expressed as mean ± SEM. Densitometric analysis shows significant upregulation of NF-κb and COX-2 expression in MIA treatment group. Lutein pre-treatment downregulated the inflammatory proteins compared to MIA treatment. **B** -- MIA treatment showed significant upregulation of IL-6, IL-1β and TNF-α in the MIA treatment group. Lutein pre-treatment downregulated the inflammatory cytokines compared to MIA treatment. \*\*\**p* \< 0.001 when compared to control group. +++*p* \< 0.001 when compared to MIA treatment. NS -- non-significant compared to control group](AMS-14-27549-g005){#f0005}

Lutein prevented MIA-induced apoptosis {#sec3.5}
--------------------------------------

The results showed that MIA treatment resulted in a significant loss of mitochondrial membrane potential with upregulation of caspase-3 activation compared to that of control cells. Treatment with lutein showed significant restoration of membrane potential with downregulation of caspase-3 activation compared to that of MIA-treated cells ([Figures 6 A](#f0006){ref-type="fig"}, [B](#f0006){ref-type="fig"}).

![Lutein inhibits apoptosis. Results are given as the mean ± SEM. Lutein pre-treatment maintained the mitochondrial membrane potential (**A**) and downregulated caspase-3 activity (**B**) compared to MIA treatment. \*\*\**P* \< 0.001 when compared to control group. +++*P* \< 0.001 when compared to MIA treatment. NS -- non-significant compared to control group (One-way ANOVA followed by Tukey's multiple comparison)](AMS-14-27549-g006){#f0006}

Discussion {#sec4}
==========

Osteoarthritis involves abnormal function of chondrocytes with deregulation in matrix proteins and cartilage structure. Until now, reports suggest that apoptosis and initial activation of oxidative stress are important contributors. In the present study, we aimed to identify the potential role of lutein in prevention of MIA-induced osteoarthritis through studying ROS generation, the Nrf2 pathway of antioxidant mechanisms, inflammation and apoptosis.

A cellular toxicity study revealed that MIA caused significant dose-dependent cell death when compared to the control group. The MIA is an established model for osteoarthritis and it results in substantial cartilage degradation through chondrocyte apoptosis *in vivo* and *in vitro* \[[@cit0023], [@cit0024]\]. In the present study, MIA treatment resulted in significant upregulation of cellular oxidant status through ROS levels, lipid peroxide content and a concomitant decrease in antioxidant status. Free radical mediated chondrocyte cell death and calcification have been reported to involve ROS, H~2~O~2~ and nitric oxide \[[@cit0014], [@cit0025]--[@cit0027]\]. Since Nrf2 is a prime regulator of redox status, its role in osteoarthritis is not well explored. In the present study, lutein treatment of chondrocyte cells showed significant protection against MIA-induced oxidative stress events which could be attributed to its potential to activate Nrf2. Nrf2, nuclear factor erythroid 2-related factor 2, is an important transcription factor which regulates the redox imbalance through upregulation of ARE-responsive antioxidant enzymes. Under oxidative stress, Nrf2 functions by cytoprotective activity, but under extremes of redox conditions leads to Nrf2 downregulation, favoring changes in normal cellular processes. Along with significant upregulation of Nrf2, lutein treatment showed increased expression of downstream genes HO-1 and NQO-1. Altogether, lutein reduces oxidative stress through upregulation of Nrf2 and the cytoprotective antioxidant system. Increased antioxidant effects have been documented *in vitro* and *in vivo* \[[@cit0028]\], and protection against LPS-induced uveitis was mediated through its antioxidant property \[[@cit0029]\]. Attenuation of neuroinflammation in micro-glia cells by lutein was mediated through inhibition of NF-κB activation and activation of Nrf2 levels \[[@cit0030]\]. Lutein prevented arsenic-induced reproductive toxicity through enhancing Nrf2 levels and their target proteins HO-1, NQO1 and GST \[[@cit0031]\].

Inflammation and onset of osteoarthritis are closely linked. In addition, oxidative stress and activation of NF-κB are well established. Nuclear factor κB is sequestered in the cytoplasm, whereas under oxidative stress it translocates into the nucleus and induces various inflammatory proteins such as COX-2 and iNOS \[[@cit0032]\].The redox-sensitive transcription factor is activated under enhanced ROS levels, and in the present study there was significant upregulation of NF-κB and COX-2 levels during MIA treatment. Inflammatory activation and release of pro-inflammatory cytokines destroy the cartilage matrix; however, ROS levels further enhance the catabolic process with negative regulation in formation of cartilage structure \[[@cit0033], [@cit0034]\]. In order to achieve a balance between these 2 metabolic processes, redox status and inflammation must be effectively downregulated. In the present study, lutein treatment showed significant downregulation in inflammatory proteins (NF-κB and COX-2) and release of pro-inflammatory cytokines. Endotoxin-induced uveitis was suppressed by lutein by its anti-inflammatory effects through suppression of activation of NF-κB, NO, TNF-α, IL-6, and PGE2 expression \[[@cit0035]\]. Oxidative stress induced inflammation in gastric epithelial cells was effectively inhibited by reducing ROS levels, inhibition of NF-κB activation and IL-8 expression \[[@cit0036]\]. Lutein prevented linoleic acid induced inflammatory gene expression and protected retinal pigment epithelial cells through inhibition of NF-κB activation \[[@cit0037]\].

In conclusion, inflammatory cytokines have a prominent role in chondrocyte mitochondrial dysfunction and cartilage destruction through redox species. Mitochondria regulate apoptosis, whereas loss of membrane potential releases apoptotic factors and induces caspase activation. Caspase-3 is a key protein involved in apoptosis and executes cell death \[[@cit0038]\]. In the present study, treatment with lutein significantly regulated MIA-induced loss of membrane potential and caspase-3 activation and prevented cell death in chondrocytes. Lutein inhibited mammary tumor through inhibition of apoptosis and angiogenesis through increased expression of the pro-apoptotic genes p53 and Bax, and decreased expression of the anti-apoptotic gene Bcl-2 \[[@cit0039]\]. Lutein along with zeaxanthin and DHA increased photoreceptor survival and differentiation by reducing oxidative stress-induced apoptosis \[[@cit0040]\]. The present study shows the promising role of lutein in protection against osteoarthritis by modulation of oxidative stress and apoptosis through Nrf2 and NF-κB expression.
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